Patients undergoing CAS may have worse outcomes if they are treated by institutions or by physicians with lower versus higher CAS volumes. Indeed, a recent study reported the existence of a learning curve for CAS and an inverse association between CAS volume and 30-day mortality 6 among Medicare beneficiaries at the level of the operating physician. The authors, however, did not have information on potentially important confounders, such as high surgical risk status or degree of carotid stenosis. Moreover, the authors did not investigate the effect of CAS hospital volume or non-CAS stenting volume on peri-procedural outcomes. The objective of this study was to assess the relationship between physician and hospital CAS volumes and hospital volume of other stenting procedures on peri-procedural mortality after CAS among Medicare patients.
Methods

Data Sources
We conducted a retrospective cohort study using the CMS CAS Database 7 (CAS-D; 2005-2009), the 2009 American Hospital Association's Annual Survey Database, 8 the 2010 American Medical Association's Physician Masterfile, 9 2000 to 2008 Medicare Provider Analysis and Review (MEDPAR) files, denominator, vital status, and Medicare institutional and noninstitutional files for Medicare patients undergoing CAS between 2000 and 2009. As a condition for CMS certification and reimbursement, facilities must submit basic clinical and procedural data on patients undergoing CAS at their facility. 7 The resulting database, the CAS-D, contains data on patient's date of birth, procedure date, institutional Medicare provider identification number, high surgical risk status, symptomatic status, degree of carotid stenosis by angiography, and embolic protection device use (see Methods in the Data Supplement for a description of the CAS-D and Figure I in the Data Supplement for carotid stenosis distribution in the CAS-D). From CMS, we obtained Medicare files from January 1, 2000, to December 31, 2009 , for all patients undergoing CAS in an inpatient setting (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes: 00.61, 00.63, 00.64). The Medicare denominator file contains information on patient demographics, eligibility, and enrolment; the institutional file includes data on inpatient and outpatient facility services covered under Medicare Parts A and B; the noninstitutional file contains information on claims submitted for physician services covered under Part B; and the vital status file has date of death information. We also obtained 100% MEDPAR data, 2000 to 2008. MEDPAR is similar to institutional Medicare files, except that it includes skilled nursing facility claims in addition to inpatient claims and are aggregated at the encounter level. We linked the CAS-D to the Medicare and MEDPAR data using a previously described highly accurate deterministic linking method. 10, 11 Briefly, we linked CAS procedures in the CAS-D to MEDPAR and the Medicare institutional file on date of birth, Medicare provider identifier, and required that the CAS-D procedure date occur during a CAS Medicare hospitalization (ICD-9-CM procedure codes: 00.61, 00.63, 00.64). We expected to link 70% to 75% of records to the CMS CAS-D and successfully linked 67%; linked and unlinked CAS-D records did not differ in mean age, carotid stenosis degree, proportion at high surgical risk, or with symptomatic stenosis. We linked the American Hospital Association's Annual Survey Database using Medicare provider identifiers to obtain information on hospitals' organizational structure, services provided, and size. We used unique physician identification numbers or national provider identifiers to link the Physician Masterfile to obtain physician demographic and practice data.
Study Cohort
Our cohort consisted of Medicare Part A-linked CAS-D patients with a corresponding Medicare Part B CAS claim within 30 days of the CAS-D procedure date (Healthcare Common Procedure Coding System codes: 37215 and 37216). The Part B claim was needed to identify the physician performing CAS. Medicare-linked CAS-D records without a corresponding Part B claim (7324, 24.5%), did not differ from records with a corresponding Part B claim (21928) in terms of mean age, sex, carotid stenosis degree, proportion at high surgical risk, or with symptomatic stenosis. In addition, we required patients to be at least 66 years of age and continuously eligible for Fee-for-Service Medicare for a least 1 year before the procedure.
Outcomes
The outcome was 30-day mortality after CAS. The date of death was obtained from the Medicare vital status file.
Measures of Physician Experience
We identified performing physicians using the unique physician identification number or national provider identifier listed in the Part B claim. We converted unique physician identification numbers to national provider identifiers using all available claims data and the
WHAT IS KNOWN
• Previous studies demonstrated that lower operator and center carotid artery stenting volumes are associated with worse peri-procedural outcomes, indicating that provider proficiency can influence patient outcomes. volume providers tended to be healthier than patients treated by lower-volume providers; the comorbidity burden was lower as was the proportion of patients who were symptomatic or nonelectively admitted for their procedure, which may be indicative of patient selection by high-volume providers.
WHAT THE STUDY ADDS
CMS unique physician identification number-national provider identifier crosswalk, 12 but were unable to convert physician identifiers for 4% of CAS procedures. We estimated physician CAS experience as follows: (1) number of CAS procedures in the past year; (2) total number of CAS procedures; (3) time (in months) since first CAS procedure; and (4) procedural volume annualized over the length of time the physician had been performing CAS. We also considered the possibility of trends in the number of CAS procedures performed over time and considered the year of the procedure as a proxy for volume. The earliest CAS procedures we could capture were in 2005 when the first CAS claims codes started appearing. To avoid extreme annualized volumes among physicians recently starting to perform CAS, we required at least 6 months of experience for the fourth measure. We did not include procedures performed on the same date because the sequencing was unclear. When >1 physician was associated with a procedure on a given date (<3%), we assigned the procedure to the physician with the highest volume. It was not possible to assess the relationship between coronary and peripheral stenting volume and CAS outcomes at the physician level because we had complete Part B claims for CAS only.
Measures of Hospital Experience
We identified CAS using ICD-9-CM procedure codes and the performing hospital using Medicare identifiers listed in Part A or MEDPAR files. We used past-year, total, annualized, and months of experience to describe hospital CAS experience. Using the MEDPAR file, we were able to explore hospital volume with other stenting procedures, such as coronary (ICD-9-CM codes: 36.06 and 36.07) and peripheral (ICD-9-CM codes: 39.90 and 00.55) stents.
Study Variables
Information on age, sex, and race was obtained from the Medicare denominator file. We identified comorbidities using validated algorithms, wherever possible, by searching institutional and noninstitutional claims in the year leading up to and including the index CAS hospitalization for ICD-9-CM codes indicative of angina (inpatient diagnosis of 411.1x 13 We used institutional and noninstitutional claims data from the year before and including the index hospitalization to calculate the Elixhauser comorbidity score 19 (see Methods and Table I in the Data Supplement for description of the Elixhauser comorbidity score and how it was derived). We calculated measures of healthcare utilization that may be predictive of mortality. 20 Patients undergoing elective CAS were those with an elective hospital admission as per the institutional Medicare file. Patients enrolled in a clinical trial were those with modifier codes indicative of enrolment in a Medicareapproved research study (Q0, Q1, QA, QV, or QR). 21 Symptomatic status in the CAS-D is defined as transient ischemic attack, nondisabling stroke, or transient monocular blindness, but does not specify laterality of symptoms. In the CAS-D, high surgical risk for complications following CEA hereafter referred to as high surgical risk is defined as meeting one or more of the following criteria: age >80, prior myocardial infarction, left ventricular ejection fraction <30%, contralateral carotid artery occlusion, New York Heart Association class III or IV heart failure, unstable angina, end-stage renal disease on dialysis, intrathoracic common carotid artery lesion, severe pulmonary disease, clinically significant cardiac disease, previous neck radiation, high cervical internal carotid artery lesion(s), restenosis of prior CEA, tracheostomy, or contralateral laryngeal nerve palsy. 7 Carotid stenosis, measured by angiography in the CAS-D, was categorized as mild (<50%), moderate (50-69%), severe (≥70%), and according to the National Coverage Determination Indication: asymptomatic (≥80%), symptomatic (50%-69%), and symptomatic (≥70%; see Appendix and Figure I in the Data Supplement for details on how carotid stenosis was measured and the distribution of carotid stenosis in CAS-D). Information on physician age, sex, international medical graduate (yes/no), number of years since medical school graduation, practice (direct patient care versus other), present employment (group practice versus not in group practice), and region (Northeast, South, Mid-West, and West) was obtained from the Physician Masterfile. We categorized physician specialty based on the information obtained from noninstitutional claims reported at the time of the procedure. From the American Hospital Association's Annual Survey Database, we categorized hospitals in terms of teaching hospital status (yes/no), hospital ownership (government, not for profit, and for profit), type (general medical and surgical, heart, other), and size (<200, 200-399, 400-599, 600-999, ≥1000 total licensed hospital beds). Hospitals with a stroke center were those which were certified by the Joint Commission as being a primary stroke center.
Statistical Analysis
Baseline characteristics are reported using percentages for categorical variables and means and standard deviations (SD) as well as medians and interquartile ranges (IQR) for continuous variables. Cutoffs for volume measures were guided by the distribution, the relationship between the different categories of volume with 30-day mortality, and for CAS by the benchmarks set in the Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial 2 and Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). 1 We report unadjusted risks and 95% confidence intervals (CI) for 30-day mortality derived from Kaplan-Meier estimators. To assess the relationship between 30-day mortality and volume or year while adjusting for clustering at the level of the physician and hospital, we used hierarchical logistic regression with random effects for physicians and hospitals using the residual pseudo-likelihood with subject-specific expansion estimation technique and the glimmix procedure in SAS. For multivariable analyses, we included an a priori set of covariates thought to be strongly related to short-term mortality risk, while being careful not to oversaturate the model (<10 events/covariate). All analyses were performed using SAS version 9.3 and 9.4 (SAS Institute, Cary, NC). The study was approved by the institutional review board of Brigham and Women's Hospital. 
Results
Study Cohort
The cohort consisted of 19 724 CAS procedures performed by 2045 physicians in 729 hospitals (Figure) . (Table 1) . Compared with patients treated by physicians who had performed at least 20 CAS in the past year, patients treated by physicians who had performed no procedures had a higher mean Elixhauser comorbidity score (5.1 versus 4.5), were more likely to be symptomatic (57.6% versus 41.6%), nonelectively admitted (31.2% versus 23.0%), treated in a teaching hospital (34.8% versus 22.8%) with a stroke center (57.4% versus 44.7%), and less likely to be enrolled in a clinical trial (9.7% versus 28.8%) or treated by a cardiologist (39.3% versus 65.4%; see Table II in the Data Supplement). Although patients treated in hospitals with the lowest (<10) compared with the highest (≥40) past-year CAS volume also tended to be less likely to be enrolled in a clinical trial (12.3% versus 31.1%), more likely to have undergone CAS nonelectively (30.0% versus 21.9%), and were more often symptomatic (57.0% versus 40.4%), they were less likely treated in teaching institutions (21.4% versus 42.7%; see Table III in the Data Supplement).
Relationship Between Physician and Hospital Past-Year CAS Volume and 30-Day Mortality
Nearly one third (N=5923; 30.0%) of patients were treated by physicians who had performed <5 CAS procedures in the past year, and less than a quarter (N=4723; 23.9%) of patients underwent CAS by a physician with a past-year CAS volume of ≥20 (Table 2 ). Lower past-year physician CAS volume was associated with higher 30-day unadjusted mortality risk (P value for trend <0.001): 2.6% (95% CI, 1.7%-3.4%) for 0 past-year CAS, 2.2% (95% CI, 1.8%-2.7%) for 1 to 4, 1.9% (95% CI, 1.5%-2.3%) for 5 to 9, 1.6% (95% CI, 1.2%-1.9%) for 10 to 19, and 1.4% (95% CI, 1.1%-1.7%) for ≥20. The trend remained after adjustment (P value for trend <0.05). Compared with patients treated by physicians who had performed ≥20 CAS in the past year, patients treated by physicians having performed no pastyear CAS procedures were 1.4 times (95% CI, 0.9-2.3) more likely to die within 30 days of the procedure ( Table 2 ). The strongest confounders of the association between 30-day mortality and physician volume were the Elixhauser comorbidity score, which exhibited a direct relationship between increasing mortality and comorbidity score, nonelective hospitalization (relative risk, 2.7; 95% CI, 2.1-3.4), and symptomatic carotid stenosis (relative risk, 1.5; 95% CI, 1.2-1.9).
One out of 5 Medicare patients (N=4011; 20.3%) underwent CAS in facilities in which <10 CAS procedures were performed in the past year, and 26.1% (N=5143) of patients were treated in institutions in which at least 40 CAS procedures were performed in the past year. We noted a similar inverse relationship between hospital volume and 30-day mortality across categories of past-year hospital CAS volume (P value for trend <0.01): 2.3% (95% CI, 1.8%-2.7%) for <10 past-year CAS, 2.1% (95% CI, 1.7%-2.5%) for 10 to 19, 1.8% (95% CI, 1.5%-2.2%) for 20 to 39, and 1.2% (95% CI, 0.9%-1.5%) for ≥40. The adjusted relative risk was 1.5 (95% CI, 1.0-2.1) for 30-day mortality after CAS for patients treated by hospitals that had performed <10 CAS procedures in the past year compared with patients undergoing CAS in institutions that had performed ≥40 CAS procedures in the past year (Table 3 ). Confounders and their strength were similar for physician and hospital volume.
Other Measures of Experience
We noted inverse associations of similar strength between 30-day mortality and total CAS and annualized CAS volume at the physician and hospital level. The association between the number of months the physician had been performing CAS and 30-day mortality was inconclusive. We also did not detect an association between year of CAS procedure and peri-procedural mortality (see Tables IV and V in the Data Supplement) .
The MEDPAR-linked CAS-D consisted of 16 100 patients undergoing CAS with patient characteristics similar to those of the overall cohort (see Table VI in the Data Supplement). Increasing past-year hospital coronary and peripheral stenting volume was associated with reduced 30-day mortality after CAS that persisted after confounder adjustment; patients undergoing CAS in hospitals having performed <200, 200 to 399, or 400 to 849 peripheral or coronary stenting procedures in the past year were 1.6 (95% CI, 1.0-2.4), 1.3 (95% CI, 0.8-1.9), and 1.1 (95% CI, 0.7-1.6) times more likely to die during the peri-procedural period, respectively, relative to hospitals having performed ≥850 peripheral or coronary stenting procedures ( Table 4 ). The results were mainly driven by coronary stenting procedures, which were far greater in number than peripheral stenting procedures, but a downward trend between past-year peripheral stenting volume and peri-procedural mortality was also evident when analyzed separately (see Tables VII-XI in the Data Supplement).
Sensitivity Analysis
CAS claims codes appear in Medicare data starting in 2005, and thus, any procedures performed before 2005 would not be captured. To evaluate the effect of underestimating past-year CAS volume, we restricted the analysis to CAS performed from 2006 onwards so that past-year CAS history would be complete. Results were robust. 
Physician Volume-Outcome Relationship
Our finding of an inverse relationship between physician CAS volume and 30-day mortality is consistent with findings from previous observational studies. 6, [22] [23] [24] [25] A recent study of 24 701 Medicare beneficiaries undergoing CAS between 2005 and 2007 using slightly different measures and cutoffs for physician volume found similar unadjusted 30-day mortality risks among high (≥24)-and low (≤6)-volume physicians (1.4% and 2.5%) and adjusted odds ratios comparing 30-day mortality among high-versus low-volume CAS physicians (1.9 [95% CI, 1.4-2.7]). 26 This volume-outcome relationship could be explained as the more procedures the physician performs, the more they develop their skills, which translates into better outcomes. Alternative explanations for these findings include: (1) physicians with greater CAS volume may be better at selecting appropriate candidates; (2) physicians with better patient outcomes may be more likely to receive patient referrals contributing to increased CAS volume; (3) high-volume providers may have higher volumes in part because their threshold to perform CAS may be lower; (4) patients with more urgent CAS need may not have the opportunity to seek out the most experienced providers and may have more severe disease. Although it is not possible in our data to differentiate between the first 3 alternative explanations, we did find differences in case mix suggestive of selection, which we were able to account for in our adjusted estimates.
Hospital Volume-Outcome Relationship
We found lower peri-procedural mortality with increasing pastyear hospital CAS volume and that healthier patients were treated at higher-volume institutions. The hospital volumeoutcome relationship was of the same magnitude as for physicians. Other studies have also detected a relationship between higher hospital CAS volumes and better patient outcomes, [27] [28] [29] as well as similar effect sizes for physicians and hospitals. 22, 29 They reported neither the unadjusted nor the adjusted measures for the association between hospital CAS volume and mortality, and so it is not possible to determine whether the findings were suggestive of a downward trend with increasing CAS volume. The correlation of hospital with physician CAS volume and the quality of aftercare provided by hospitals may explain better outcomes at higher-volume CAS and stenting hospitals.
Mortality Among Medicare Patients Versus Landmark Trials
Peri-procedural mortality in our study was 1.8% compared with 0.7% and 0.6% in the landmark clinical trials CREST 1 and SAPPHIRE, 2 respectively. These trials enrolled physicians only after having demonstrated substantial CAS proficiency with low complication rates. SAPPHIRE interventionalists performed a median of 64 lifetime CAS procedures (range 20-700) and had complication rates <6%, whereas CREST physicians were enrolled after evaluation of their endovascular volumes, CAS outcomes, and after participation in a leadin study. CREST peri-procedural complication rates were the lowest of any carotid revascularization trial (6% for peri-procedural stroke and death among symptomatic patients 1 ), and physicians participating in the lead-in study had submitted a median of 29 lifetime CAS procedures. 5 Although the CASspecific codes became available only in 2005, the relative proportion of pre-2005 procedures we could not capture is likely to be small given the patterns of CAS diffusion among Medicare beneficiaries following the National Coverage Determination. The median number of CAS procedures performed by physicians since 2005 in our study was 17. Assuming that ≈70% of CAS procedures were performed on Medicare beneficiaries,26 the median CAS volume would increase to 24 which is still less than in SAPPHIRE or CREST. Differences in peri-procedural mortality risks between Medicare and SAP-PHIRE or CREST patients is likely stems from differences in patient characteristics as well as factors related to provider proficiency, including appropriate patient selection and lifetime CAS volume.
Strengths and Limitations
One of the major strengths of this study is that we were able to evaluate and adjust for important clinical and procedural factors, such as high surgical risk status 31 and symptomatic status, 32 which have been associated with poor outcomes after CAS. In using mortality as the outcome, we selected the hardest and most reliable end point. We also explored different ways of categorizing CAS volume (past year, cumulative volume since 2005, annualized, months of experience) and explored the association between volume of other stenting procedures on peri-procedural CAS mortality.
The findings from this study should be interpreted in context of a number of limitations. We were only able to capture procedures performed in Medicare beneficiaries, which may have resulted in the misclassification of past-year volume. However, during the study period, the majority of CAS (≈70%), coronary stenting (50%), and peripheral stenting (70%) procedures were performed in Medicare patients. 26 Given our inability to capture CAS procedures performed before 2005 because of the lack of a specific code, misclassification of past-year CAS volume is likely highest for procedures done in 2005. Restricting the analysis to procedures performed from 2006 onwards revealed that results were robust. In addition, although we could investigate the volume-outcome relationship for CAS at the physician and hospital level, we could only investigate the relationship between coronary and peripheral stenting volume and CAS outcomes at the hospital level. Moreover, given that we lacked cause of death information, it was not possible to determine whether patients died of complications relating to the procedure (eg, stroke) or other, unrelated factors (eg, trauma) during the peri-procedural period. Finally, we cannot rule out the possibility of residual confounding because of mismeasurement of potential confounders (ie, symptomatic status, Elixhauser comorbidity score).
Conclusions
CAS is a relatively new approach to carotid revascularization, is a technically complex procedure, and is becoming a widely accepted procedure for the treatment of carotid artery stenosis. The majority of Medicare patients in our study were treated by providers with low past-year CAS volume (median, 9 for physicians and 23 for hospitals), and we found a substantially lower risk of peri-procedural mortality after CAS among patients treated by high-volume providers. Peri-procedural mortality may be used to monitor the safety and effectiveness of CAS in routine clinical practice. As the procedural technology evolves and the procedure itself becomes more widely disseminated, periodic monitoring of peri-procedural complications after CAS may help in assessing the appropriateness of patient selection and in updating training and proficiency requirements for CAS providers, as necessary. 
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